COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
Srikanth Muppidi(Stanford Health Care), John Vissing(University of Copenhagen), Ana Paula Sousa, Paul Maddison, Philip Alexander Ambrose(Fondazione IRCCS Istituto Neurologico Carlo Besta), Ikjae Lee(Columbia University Irving Medical Center), Michelle Kaku(Icahn School of Medicine at Mount Sinai), Mahtab Ramezani(Shahid Beheshti University of Medical Sciences), Amanda C. Guidon(Harvard University), Jinny Tavee(National Jewish Health), Renato Mantegazza(Italian Association for Cancer Research), Paul R. Gallagher, Saiju Jacob(Institute of Immunology), Michael K. Hehir(University of Vermont), Gary Cutter(Epilepsy Foundation), James F. Howard(University of North Carolina at Chapel Hill), Heinz Wiendl(University Medical Center Freiburg), Alok Tyagi(Queen Elizabeth University Hospital), Isabel Illa(Hospital de Sant Pau), Jeffrey T. Guptill(Duke University), Ashwin Pinto, James B. Caress(The University of Texas at San Antonio Health Science Center), Henry J. Kaminski(George Washington University), Richard J. Nowak(Yale University), Dubravka Dodig, Bhaskar Roy(Yale University), Hiroyuki Murai(Kyushu University), Matthew B. Maas(Northwestern University), Caroline Carmichael(Queen Elizabeth University Hospital), Natalia Jiménez Esquivel, Yingkai Li(Sun Yat-sen University), Mathew Maas(Northwestern University), Anthony A. Amato(Brigham and Women's Hospital), Maria Elena Farrugia(Queen Elizabeth University Hospital), Georgina Burke, Kamla Best, Jane Pritchard(University of California, Los Angeles)
Cited by 121
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
|The Lancet Neurology|2017|820
Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia
|Annals of Neurology|2010|728
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706